PACIRA BIOSCIENCES, INC. Net Fee Amt
PACIRA BIOSCIENCES, INC. (PCRX) had Net Fee Amt of $2.94 thousand as of 2026-08-04, per its S-8 filed 2026-08-04.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-04
- 2026-08-04: Net Fee Amt $2.94K.
| Period end | Net Fee Amt |
|---|---|
| 2026-08-04 | $2.94K S-8 · filed 2026-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |